Denmark· DK-28106216619
ELZONRIS
A tagraxofusp product containing tagraxofusp, registered in Denmark by Stemline Therapeutics B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Tagraxofusp is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XX67 (tagraxofusp), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Tagraxofusp · ATC L01XX67
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Tagraxofusp
- Manufacturer
- Stemline Therapeutics B.V.
- Country
- Denmark (DK)
- ATC code
- L01XX67
- ATC class
- Tagraxofusp
- Defined daily dose
- 0.2 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106216619
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for tagraxofusp.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tagraxofusp · interactions on record
82 records
- 9 severe
- 73 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XX67
Tagraxofusp, as other registers publish it.
- United StatesElzonrisStemline Therapeutics, Inc.
- SwitzerlandElzonris
- FinlandELZONRISStemline Therapeutics B.V.
- PolandELZONRISStemline Therapeutics B.V.
- IcelandELZONRISStemline Therapeutics B.V.
- CzechiaELZONRISStemline Therapeutics B.V., Amsterdam
- BelgiumElzonris 1 mg/mlStemline Therapeutics
- IrelandELZONRIS 1 mg/mL concentrate for solution for infusionTMC Pharma (EU) Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af155686-9a48-4d48-856d-d7c78b9d0b64 GET /v1/drugs/af155686-9a48-4d48-856d-d7c78b9d0b64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "1 mg/ml",
"auth_role": "MOD",
"dk_drugid": "28106216619",
"substance": "Tagraxofusp",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "44203"
}See everything about tagraxofusp.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.